Sign Out
Asthma: Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonists.
Relvar Ellipta is indicated for the regular treatment of asthma in adults aged 18 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.
100/2.5 mcg: COPD (Chronic Obstructive Pulmonary Disease): Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
